Author + information
Metabolic syndrome (MS), an important component of insulin resistance and cardiovascular (CV) risk, is defined by 3 or more of the following characteristics: abdominal obesity, hyperglycemia, hypertension, hypertriglyceridemia, and hypo-high-density lipoprotein cholesterolemia. MS is used to identify patients at increased risk for cardiovascular disease, type II diabetes mellitus, and all-cause mortality. The aim of this work to assess the effects of telmisartan/amlodipine combination compared to singles monotherapies on blood pressure control, and levels of some new emerging biomarkers in cardiovascular risk stratification in hypertensive patients with metabolic syndrome.
92 hypertensive patients with metabolic syndrome were randomly assigned to telmisartan 40 mg, amlodipine 10 mg or combination of telmisartan/amlodipine 40/10 mg for 24 weeks. We evaluated at the baseline, and after 12 and 24 weeks the following parameters: systolic and diastolic blood pressure, lipoprotein (a), paraoxonase-1, isoprostanes.
Blood pressure was reduced by all treatments, even if SBP and DPB were better decreased by telmisartan/amlodipine combination compared to amlodipine and telmisartan monotherapies (p<0.02). Regarding levels of some new emerging biomarkers, telmisartan/amlodipine decreased lipoprotein (a), and isoprostanes levels and increased paraoxonase-1levels after 24 weeks both compared to baseline (p<0.04), and to single monotherapies (p<0.05).
Telmisartan/amlodipine combination is more effective in lowering blood pressure, more than monotherapies alone. This combination has also a beneficial effect on reducing levels of some new emerging biomarkers such as lipoprotein (a), paraoxonase-1, isoprostanes in CV risk assessment.